PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8745363

Endothelium, for example.

A Henderson
View original source ↗Export metadata ↓

Abstract

Endothelial nitric oxide production contributes at many levels to cardiovascular efficiency (considered as tissue perfusion relative to cardiac work). Endothelial dysfunction is found in many conditions, including all known risk factors for atheroma, and is usually generalised, when present, involving microvessels as well as large arteries, impairing cardiovascular efficiency and potentially initiating atheroma. Loss of flow-related dilation is a manifestation of endothelial dysfunction and can be measured non-invasively, thereby providing a potential marker of reversible atherogenic susceptibility.

Explore related subjects

ArteriosclerosisCardiovascular DiseasesEndothelium, VascularHumansInsulin ResistanceMicrovascular AnginaNitric OxideJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Henderson. Endothelium, for example.. https://pubmed.ncbi.nlm.nih.gov/8745363/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Atherosclerosis: a unifying disorder with diverse manifestations.

The epidemiology, costs, and comorbidities associated with atherosclerosis and the role of newer antiplatelet agents are reviewed. Cardiovascular disease is the leading cause of death in the United States. More than 60 million Americans have one or more types of cardiovascular disease. The total annual cost of coronary heart disease has been estimated at $95 billion. Patients with an existing atherosclerotic disease in one vascular bed are at high risk of having an ischemic vascular event in the same or another vascular bed. Peripheral arterial disease is a strong marker for underlying cerebrovascular and cardiovascular disease. The common link among these diseases is atherosclerosis leading to atherothrombosis. Platelets play an integral role in atherosclerosis and the formation of arterial thrombus as well as in subsequent acute events such as ischemic stroke, myocardial infarction, and vascular death. Arterial thrombosis can be mediated by shear-stress-induced platelet aggregation. Currently, only one third to one half of all eligible patients with stroke, myocardial infarction, or peripheral arterial disease receive antiplatelet therapy. Thienopyridines such as ticlopidine and clopidogrel are effective inhibitors of shear-stress-induced and endothelial-injury-induced platelet aggregation. Advances in antiplatelet therapy provide an opportunity to use newer antiplatelet agents in the prevention of atherosclerosis-related morbidity and mortality; therapeutic approaches should be directed toward recognizing atherosclerosis as a generalized disease process and preventing ischemic events in multiple vascular beds.

Arteriosclerosis↗